PriceTargets.com logo

Psyence Biomedical - PBM Stock Price Target and Predictions

  • Consensus Rating: Sell
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 1
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$1.81 As of 12/4/2025 05:00 PM ET
▲ +0.03 (1.69%)

This chart shows the closing price for PBM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Psyence Biomedical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PBM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PBM

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Psyence Biomedical in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $1.81.

This chart shows the closing price for PBM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Sell

The current consensus among 1 investment analysts is to sell stock in Psyence Biomedical.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/13/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/11/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/10/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/10/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/8/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/6/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/5/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/5/2025

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/8/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/27/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
(Data available from 12/5/2020 forward)

News Sentiment Rating

0.24 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/9/2025
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/8/2025
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/8/2025
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/7/2025
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/6/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/6/2025
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/5/2025
  • 1 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/5/2025

Current Sentiment

  • 1 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Psyence Biomedical logo
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.
Read More

Today's Range

Now: $1.81
Low: $1.71
High: $1.88

50 Day Range

MA: $2.82
Low: $1.49
High: $4.44

52 Week Range

Now: $1.81
Low: $1.41
High: $62.96

Volume

200,104 shs

Average Volume

1,179,510 shs

Market Capitalization

$3.38 million

P/E Ratio

0.45

Dividend Yield

N/A

Beta

0.28

Frequently Asked Questions

What sell-side analysts currently cover shares of Psyence Biomedical?

The following Wall Street research analysts have issued research reports on Psyence Biomedical in the last year: Wall Street Zen, and Weiss Ratings.
View the latest analyst ratings for PBM.

What is the current price target for Psyence Biomedical?

0 Wall Street analysts have set twelve-month price targets for Psyence Biomedical in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Psyence Biomedical in the next year.
View the latest price targets for PBM.

What is the current consensus analyst rating for Psyence Biomedical?

Psyence Biomedical currently has 1 sell rating from Wall Street analysts. The stock has a consensus analyst rating of "Sell." A "sell" rating indicates that analysts believe PBM will underperform the market and that investors should sell shares of Psyence Biomedical.
View the latest ratings for PBM.

What other companies compete with Psyence Biomedical?

Other companies that are similar to Psyence Biomedical include FibroBiologics, Curanex Pharmaceuticals, VYNE Therapeutics, Bullfrog AI and Imunon. Learn More about companies similar to Psyence Biomedical.

How do I contact Psyence Biomedical's investor relations team?

Psyence Biomedical's physical mailing address is 2201 BROADWAY SUITE 705, OAKLAND CA, 94612. The company's listed phone number is 510-214-3750 and its investor relations email address is [email protected]. The official website for Psyence Biomedical is www.psyencebiomed.com. Learn More about contacing Psyence Biomedical investor relations.